Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BTM-3566 in Relapsed/Refractory Mature B Cell Lymphomas
NCT06792734Phase 1Recruiting
- Sponsor
- Bantam Pharmaceutical
- Start
- Feb 2025
- Primary completion
- Feb 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of BTM-3566 in mature B-cell lymphoma, sponsored by Bantam Pharmaceutical. Primary endpoint: Adverse Event and dose-limiting toxicity event rates at 24 months. Started Feb 2025; status: recruiting.
02
Drugs
BTM-3566
03
Conditions
mature B-cell lymphoma
Beyond the preview
Go deeper on NCT06792734.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06792734.